Yesterday, Feb. 2, 2016, 51 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $704.60 to $1,889,600.00.

Highlighted Stocks Traded by Insiders:

United Technologies (UTX) - FREE Research Report

Reynolds Fredric G, who is Director at United Technologies, bought 12,000 shares at $86.20 on Feb. 2, 2016. Following this transaction, the Director owned 13,225 shares meaning that the stake was boosted by 979.59% with the 12,000-share transaction.

The shares most recently traded at $85.32, down $0.88, or 1.03% since the insider transaction. Historical insider transactions for United Technologies go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for United Technologies has been 6.0 million shares per day over the past 30 days. United Technologies has a market cap of $77.7 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are down 11.09% year-to-date as of the close of trading on Tuesday.

United Technologies Corporation provides technology products and services to building systems and aerospace industries worldwide. The stock currently has a dividend yield of 2.92%. The company has a P/E ratio of 13.9. Currently, there are 7 analysts who rate United Technologies a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UTX - FREE

TheStreet Quant Ratings rates United Technologies as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, poor profit margins and disappointing return on equity. Get the full United Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cullen/Frost Bankers (CFR) - FREE Research Report

Alvarez Carlos, who is Director at Cullen/Frost Bankers, bought 40,000 shares at $47.24 on Feb. 2, 2016. Following this transaction, the Director owned 370,000 shares meaning that the stake was boosted by 12.12% with the 40,000-share transaction.

The shares most recently traded at $46.20, down $1.04, or 2.25% since the insider transaction. Historical insider transactions for Cullen/Frost Bankers go as follows:

  • 4-Week # shares bought: 539
  • 4-Week # shares sold: 2,216
  • 12-Week # shares bought: 539
  • 12-Week # shares sold: 2,216
  • 24-Week # shares bought: 539
  • 24-Week # shares sold: 2,216

The average volume for Cullen/Frost Bankers has been 959,200 shares per day over the past 30 days. Cullen/Frost Bankers has a market cap of $2.9 billion and is part of the financial sector and banking industry. Shares are down 23.87% year-to-date as of the close of trading on Tuesday.

Cullen/Frost Bankers, Inc. operates as the bank holding company for Frost Bank that offers commercial and consumer banking services in Texas. The company operates through two segments, Banking and Frost Wealth Advisors. The stock currently has a dividend yield of 4.51%. The company has a P/E ratio of 11.0. Currently, there is 1 analyst who rates Cullen/Frost Bankers a buy, 4 analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFR - FREE

TheStreet Quant Ratings rates Cullen/Frost Bankers as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and unimpressive growth in net income. Get the full Cullen/Frost Bankers Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Aratana Therapeutics (PETX) - FREE Research Report

Tooman Craig A, who is Chief Financial Officer at Aratana Therapeutics, sold 2,806 shares at $3.36 on Feb. 2, 2016. Following this transaction, the Chief Financial Officer owned 102,424 shares meaning that the stake was reduced by 2.67% with the 2,806-share transaction.

The shares most recently traded at $3.27, down $0.09, or 2.84% since the insider transaction. Historical insider transactions for Aratana Therapeutics go as follows:

  • 4-Week # shares sold: 3,620
  • 12-Week # shares sold: 3,620
  • 24-Week # shares bought: 10,333
  • 24-Week # shares sold: 6,870

The average volume for Aratana Therapeutics has been 576,500 shares per day over the past 30 days. Aratana Therapeutics has a market cap of $117.3 million and is part of the health care sector and drugs industry. Shares are down 42.65% year-to-date as of the close of trading on Tuesday.

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Currently, there are 6 analysts who rate Aratana Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETX - FREE

TheStreet Quant Ratings rates Aratana Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Aratana Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Data for this article provided by Zacks Investment Research